Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study

Laurence, 2015, Costs to health services and the patient of treating tuberculosis: a systematic literature review, Pharmacoeconomics, 33, 939, 10.1007/s40273-015-0279-6 Conradie, 2014, Clinical access to bedaquiline programme for the treatment of drug-resistant tuberculosis, Afr Med J, 104, 164, 10.7196/SAMJ.7263 2020 Klopper, 2020, A landscape of genomic alterations at the root of a near-untreatable tuberculosis epidemic, BCM Med, 18, 1 van Dorp, 2023, Detection of a bedaquiline/clofazimine resistance reservoir in Mycobacterium tuberculosis predating the antibiotic era, bioRxiv De Vos, 2019, Bedaquiline microheteroresistance after cessation of tuberculosis treatment, N Engl J Med, 380, 2178, 10.1056/NEJMc1815121 Ghodousi, 2019, Acquisition of cross-resistance to bedaquiline and clofazimine following treatment for tuberculosis in Pakistan, Antimicrob Agents Chemother, 63, e00915, 10.1128/AAC.00915-19 Pang, 2017, In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China, Antimicrob Agents Chemother, 61, e00900, 10.1128/AAC.00900-17 Omar, 2022, Bedaquiline-resistant tuberculosis associated with Rv0678 mutations, N Engl J Med, 386, 93, 10.1056/NEJMc2103049 Conradie, 2020, Treatment of highly drug-resistant pulmonary tuberculosis, N Engl J Med, 382, 893, 10.1056/NEJMoa1901814 Nimmo, 2020, Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis, Lancet Microbe, 1, e165, 10.1016/S2666-5247(20)30031-8 Kadura, 2020, Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid, J Antimicrob Chemother, 75, 2031, 10.1093/jac/dkaa136 2021 Olayanju, 2018, Long-term bedaquiline-related treatment outcomes in patients with extensively drug resistant tuberculosis from South Africa, Eur Respir J, 51, 10.1183/13993003.00544-2018 Mudaly 2013 Torrea, 2015, Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system, J Antimicrob Chemother, 70, 2300, 10.1093/jac/dkv117 Andries, 2005, A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis, Science, 307, 223, 10.1126/science.1106753 Warren, 2006, Safe Mycobacterium tuberculosis DNA extraction method that does not compromise integrity, J Clin Microbiol, 44, 254, 10.1128/JCM.44.1.254-256.2006 Dippenaar, 2019, Whole genome sequencing provides additional insights into recurrent tuberculosis classified as endogenous reactivation by IS6110 DNA fingerprinting, Infect Genet Evol, 75, 10.1016/j.meegid.2019.103948 Cox, 2014, Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa, Int J Tuberc Lung Dis, 18, 441, 10.5588/ijtld.13.0742 Ismail, 2021, Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis, Lancet Microbe, 2, e604, 10.1016/S2666-5247(21)00175-0 Chesov, 2022, Emergence of bedaquiline resistance in a high tuberculosis burden country, Eur Respir J, 59, 10.1183/13993003.00621-2021 Villellas, 2016, Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline, J Antimicrob Chemother, 72, 684 Antoine, 2021, Intragenic distribution of IS6110 in clinical Mycobacterium tuberculosis strains: bioinformatic evidence for gene disruption leading to underdiagnosed antibiotic resistance, Microbiol Spectr, 9, 10.1128/Spectrum.00019-21 Engelthaler, 2019, Minority Mycobacterium tuberculosis genotypic populations as an indicator of subsequent phenotypic resistance, Am J Respir Cell Mol Biol, 61, 789, 10.1165/rcmb.2019-0178LE Nguyen, 2018, Bedaquiline resistance: its emergence, mechanism, and prevention, Clin Infect Dis, 66, 1625, 10.1093/cid/cix992 Mirzayev, 2021, World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update, Eur Respir J, 57, 10.1183/13993003.03300-2020 Ismail, 2018, Defining bedaquiline susceptibility, resistance, cross-resistance and associated genetic determinants: a retrospective cohort study, EBioMedicine, 28, 136, 10.1016/j.ebiom.2018.01.005 Pai, 2022, Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis, BMC Infect Dis, 22, 1, 10.1186/s12879-022-07861-x